Lv1
78 积分 2022-09-13 加入
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
13天前
已完结
Examining pre-analytical factors for bioanalysis of protein therapeutics crossing the blood–brain barrier through receptor-mediated transcytosis
13天前
已关闭
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
26天前
已关闭
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
1个月前
已关闭
Mitigation of pre-existing immunogenicity in ADA method development
1个月前
已完结
CT-P39: An Omalizumab Biosimilar
1个月前
已完结
Immunocapture-LC-MS/MS Method for Quantification of the Anti-Alzheimer’s Monoclonal Antibody Donanemab in Human and Mice Serum
1个月前
已完结
Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs
2个月前
已完结
Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs)
2个月前
已完结
Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice
5个月前
已完结
皖公网安备34019202002308
